GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Cash Conversion Cycle

Apyx Medical (Apyx Medical) Cash Conversion Cycle : 276.38 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Apyx Medical's Days Sales Outstanding for the three months ended in Mar. 2024 was 118.07.
Apyx Medical's Days Inventory for the three months ended in Mar. 2024 was 209.46.
Apyx Medical's Days Payable for the three months ended in Mar. 2024 was 51.15.
Therefore, Apyx Medical's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 276.38.


Apyx Medical Cash Conversion Cycle Historical Data

The historical data trend for Apyx Medical's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical Cash Conversion Cycle Chart

Apyx Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 162.59 200.36 162.45 254.47 246.25

Apyx Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 258.73 260.75 296.67 213.87 276.38

Competitive Comparison of Apyx Medical's Cash Conversion Cycle

For the Medical Devices subindustry, Apyx Medical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apyx Medical's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Apyx Medical's Cash Conversion Cycle falls into.



Apyx Medical Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Apyx Medical's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=85.85+213.23-52.83
=246.25

Apyx Medical's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=118.07+209.46-51.15
=276.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apyx Medical  (NAS:APYX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Apyx Medical Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Apyx Medical (Apyx Medical) Business Description

Traded in Other Exchanges
Address
5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Executives
Todd Hornsby officer: Executive Vice President 14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine director 75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb officer: Chief Financial Officer 5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal director 5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty director 1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman director 5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres director 86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers officer: Chief Financial Officer 4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron director, officer: President
Robert Gershon director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii officer: Chief CommercializationOfficer 23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson director C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz officer: Vice President of Operations

Apyx Medical (Apyx Medical) Headlines

From GuruFocus